Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3

被引：0
|
作者：
van de Kerkhof, P. [1 ]
Guenther, L. [2 ]
Gottlieb, A. [3 ]
Sebastian, M. [4 ]
Wu, J. [5 ]
Foley, P. [6 ]
Morita, A. [7 ]
Goldblum, O. [8 ]
Zhang, L. [9 ]
Erickson, J. [9 ]
Ball, S. [9 ]
Rich, P. [10 ]
机构：
[1] Radboud Univ Nijmegan, Med Ctr, Nijmegen, Netherlands
[2] Guenther Dermatol Res Ctr, London, ON, Canada
[3] Tufts Med Ctr, Boston, MA USA
[4] Hautarztpraxis Mahlow, Blankenfelde Mahlow, Germany
[5] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[6] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[7] Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Oregon Hlth & Sci Univ, Ctr Hlth & Healing, Portland, OR 97201 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
fingernail psoriasis; ixekizumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P138
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) (vol 77, pg 855, 2017)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 301 - 301
  • [22] Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1
    Rich, P.
    Bourcier, M.
    Sofen, H.
    Fakharzadeh, S.
    Wasfi, Y.
    Wang, Y.
    Kerkmann, U.
    Ghislain, P. -D.
    Poulin, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 398 - 407
  • [23] Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study
    Kleyn, C. E.
    Gooderham, M.
    Kristensen, L. E.
    de Vlam, K.
    Schuster, C.
    Leage, S. Liu
    McKenzie, R.
    Sapin, C.
    Li, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 70 - 71
  • [24] Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
    Duffin, K. Callis
    Bagel, J.
    Bukhalo, M.
    Clement, I. J.
    Choi, S. L.
    Zhao, F.
    Gill, A.
    Pangallo, B.
    Shuler, C.
    Mallbris, L.
    Jackson, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 107 - 113
  • [25] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [26] The impact of ixekizumab treatment on health-related quality of life in patients with moderate-to-severe psoriasis: results from UNCOVER-1
    Augustin, M.
    Gordon, K.
    Nikai, E.
    Edson-Heredia, E.
    Zhu, B.
    Goldblum, O. M.
    Carlier, H.
    Langley, R. G.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E9 - E9
  • [27] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [28] Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)
    Gordon, Kenneth
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel K.
    Erickson, Janelle
    Zhao, Fangyi
    Shrom, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Leonardi, Craig
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [29] Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
    Puig, Luis
    Dossenbach, Martin
    Berggren, Lovisa
    Ljungberg, Anders
    Zachariae, Claus
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (11) : 971 - 977
  • [30] EFFICACY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AND WITHOUT MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMIZED OPEN-LABEL STUDY
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Bradley, Andrew
    Moszaros, Gabriella
    De Vlam, Kurt
    Mora Alfonso, Sergio Alexander
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S140 - S141
12345